Table 2.
Multivariable cox regression, PFS and OS.
| Characteristic | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| TSG-alt (vs TSG-normal) | 2.37 (1.42–3.96) | <0.001 | 1.94 (0.98–3.86) | 0.06 |
| Treatment with ADT + D (vs ADT + A) | 1.36 (0.81–2.28) | 0.20 | 1.80 (0.84–3.83) | 0.13 |
| Prior treatment (vs none) | ||||
| Surgery | 1.16 (0.48–2.77) | 0.70 | 0.90 (0.28–2.89) | 0.90 |
| RT | 0.40 (0.13–1.22) | 0.11 | 0.76 (0.15–3.91) | 0.70 |
| High disease volume (vs low) | 1.82 (0.99–3.33) | 0.05 | 0.98 (0.41–2.32) | >0.90 |
| Mets at diagnosis (vs none) | 0.34 (0.15–0.76) | 0.009 | 1.18 (0.41–3.45) | 0.80 |
ADT + A androgen deprivation therapy plus abiraterone acetate, ADT + D androgen deprivation therapy plus docetaxel, HR hazard ratio, Mets metastases, OS overall survival, PFS progression-free survival, RT radiotherapy, TSG-alt tumor suppressor gene alteration.